- Home
- CLGN vs RFL Comparison
CLGN vs RFL Comparison
Compare CLGN & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- RFL
- Stock Information
- Founded
- CLGN 2004
- RFL 2017
- Country
- CLGN Israel
- RFL United States
- Employees
- CLGN N/A
- RFL N/A
- Industry
- CLGN Industrial Specialties
- RFL Real Estate
- Sector
- CLGN Health Care
- RFL Finance
- Exchange
- CLGN Nasdaq
- RFL Nasdaq
- Market Cap
- CLGN 44.1M
- RFL 48.4M
- IPO Year
- CLGN N/A
- RFL N/A
- Fundamental
- Price
- CLGN $4.19
- RFL $1.84
- Analyst Decision
- CLGN Strong Buy
- RFL
- Analyst Count
- CLGN 2
- RFL 0
- Target Price
- CLGN $12.50
- RFL N/A
- AVG Volume (30 Days)
- CLGN 18.1K
- RFL 26.3K
- Earning Date
- CLGN 11-27-2024
- RFL 12-12-2024
- Dividend Yield
- CLGN N/A
- RFL N/A
- EPS Growth
- CLGN N/A
- RFL N/A
- EPS
- CLGN N/A
- RFL N/A
- Revenue
- CLGN $689,000.00
- RFL $637,000.00
- Revenue This Year
- CLGN N/A
- RFL N/A
- Revenue Next Year
- CLGN $670.03
- RFL N/A
- P/E Ratio
- CLGN N/A
- RFL N/A
- Revenue Growth
- CLGN N/A
- RFL 128.32
- 52 Week Low
- CLGN $3.61
- RFL $1.29
- 52 Week High
- CLGN $6.99
- RFL $2.50
- Technical
- Relative Strength Index (RSI)
- CLGN 51.28
- RFL 46.69
- Support Level
- CLGN $3.61
- RFL $1.74
- Resistance Level
- CLGN $4.39
- RFL $1.96
- Average True Range (ATR)
- CLGN 0.23
- RFL 0.10
- MACD
- CLGN 0.09
- RFL -0.01
- Stochastic Oscillator
- CLGN 59.79
- RFL 40.00
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.